UNSPSC 51152040: Stercuronium

This classification denotes a muscle relaxant with the molecular formula C26H43N2.I, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K1477R7DDR, chemically known as (cona-4,6-dienin-3beta-yl)dimethylethylammonium iodide but generally known as stercuronium iodide, which bears US NIH Compound Identifier 71924. European Medicines Agency schedules Stercuronium iodide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10646MIG. The term STERCURONIUM IODIDE is an International Non-Proprietary Name.

As of Q4 2014, STERCURONIUM remains the US FDA Preferred Term for this commodity. SMILES: I.N1(CC23C(C4C(CC3)C3(C(=CC([N](CC)(C)C)CC3)C=C4)C)CCC2C1C)C.

UNSPSC 51152040 Stercuronium is a Commodity code that in recent state and local solicitations covers naloxone, drug deactivation systems, and related pharmaceutical products procured to support community health and public safety initiatives. State and local health and human services agencies are the primary issuing bodies under this code, including county health departments and state pharmacy benefit programs. The work involves procurement of finished pharmaceutical products and safety systems for distribution through established public health channels, with vendors responsible for managing supply chains, meeting compliance certifications (E-Verify, drug-free workplace), and maintaining insurance coverage including workers' compensation and commercial general liability.

Activity under the code appears concentrated in the Southeast and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response due July 26, 2023, on a fixed-fee basis with an initial two-year term and one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, soliciting vendor capabilities and market intelligence on implementing a direct-to-manufacturer prescription program for self-insured employee group health plans and state agencies outside traditional pharmacy benefit manager arrangements. The Texas RFI represents preliminary market research prior to formal RFP release and does not indicate award value or binding procurement timeline.